Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Controlled Phase III Study Investigating IMA901 Multipeptide Cancer Vaccine in Patients Receiving Sunitinib as First-line Therapy for Advanced/Metastatic Renal Cell Carcinoma

Next Previous
Trial Profile

A Randomized, Controlled Phase III Study Investigating IMA901 Multipeptide Cancer Vaccine in Patients Receiving Sunitinib as First-line Therapy for Advanced/Metastatic Renal Cell Carcinoma

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IMA 901 (Primary) ; Sunitinib (Primary) ; Cyclophosphamide
  • Indications Renal cancer; Renal cell carcinoma
  • Focus Registrational; Therapeutic Use
  • Acronyms IMPRINT
  • Sponsors immatics biotechnologies GmbH

Most Recent Events

  • 03 Oct 2016 Efficacy and safety results (n=339) published in the Lancet Oncology.
  • 17 Aug 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
  • 16 Jul 2014 According to an immatics Biotechnologies media release, final data from the study are expected in 2015.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top